What question did this study set out to answer?

This study aims to evaluate clinical characteristics, treatment outcomes, and prognostic factors in pediatric rhabdomyosarcoma patients.

June 6, 2026CancersOpen Access

Clinical Characteristics and Survival Outcomes in a Cohort of Pediatric Rhabdomyosarcoma Patients: The Impact of Risk-Adapted Therapy

View Full Paper

Ask AI

Bookmark

Authors

Randomized trial examines survival outcomes in pediatric rhabdomyosarcoma, highlighting the importance of tumor resection status.

This study aims to evaluate clinical characteristics, treatment outcomes, and prognostic factors in pediatric rhabdomyosarcoma patients.
Analyzed data from 76 rhabdomyosarcoma patients treated at Shanghai Children’s Hospital from 2011 to 2024.
Estimated event-free survival (EFS) and overall survival (OS) based on treatment regimens Rs-99 and modified Rs-2018.
Conducted univariate survival analysis to identify factors associated with survival.
5-year EFS for the entire cohort was 71.1% (95% CI, 62.3% to 83.3%) and OS was 72.4% (95% CI, 64.0% to 84.5%).
5-year EFS and OS for patients with metastatic disease were 35.0% (95% CI, 18.3% to 57.6%) and 40.0% (95% CI, 27.3% to 75.3%), respectively.
100% EFS for patients with R0 resection compared to 46.7% (95% CI, 25.2% to 74.0%) for R2 resection in localized disease.

Li et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark